BIOCREDE INC. — Department of Health and Human Services SBIR Phase I: 300

Description

DESCRIPTION provided by applicant Our product will monitor intravenous IV blood lactate levels for andgt days of critical ill patients with sepsis organ failure trauma or acute inflammatory response in the ICU and infant patients with congenital heart disease CHD recovering from cardiopulmonary bypass CPB surgery This device will alert doctors or nurses at the ICU when dangerous lactate increase rates are present allowing early intervention to reduce life threatening complications Our sensors possess our proprietary NO releasing coating that prevent infection thrombosis and blockages for andgt days that would otherwise render IV sensors inoperable inaccurate within minutes This device would enable discrimination between infants at high and low risk of morbidity and mortality after CHD surgery to prevent sudden infant death undergoing CPB surgery and significantly reduce hospital mortality in patients with hyperlactatemia The Meyerhoff lab has been working on various NO releasing technologies for andgt yrs and the chemistries used to date have had significant limitations that have heretofore prevented translational efforts The low cost and robustness of our newest IP protected compounds have completely overcome prior issues and enabled rapid translation of this IV blood lactate sensing technology to clinical practice affordably We are targeting the markets of pediatric interventional cardiology and adult patients with hyperlactatemia at ICU admission with sepsis organ failure trauma or acute inflammatory response syndrome The pediatric interventional cardiology market is estimated at $ MM by with a CAGR of the blood and electrolyte testing market was $ B in with a CAGR of $ MM by and the global sepsis therapeutics market is estimated to be $ B by with a CAGR of PUBLIC HEALTH RELEVANCE Lactate levels and lactate increase rate monitoring are valuable parameters in the early resuscitation of critically ill patients with organ failure and sepsis and infants with congenital heart disease requiring cardiopulmonary bypass Monitoring blood lactate increase rate is a critical marker to distinguish high and low risk of patient morbidity in the ICU and indicate a shift from aerobic to anaerobic respiration A device that can continuously quantitate blood lactate in real time will better predict blood lactate rate changes than hour discrete measurements now conducted on benchtop blood analyzers to prevent sudden patient death